cognizance of these gaps, i3 is
focussed on targeted measures to
develop platform technologies for
product validation, link disparate
institutions to strengthen clinical
trial networks, promote partial
de-risking for novel products,
and build capacities in emerging
areas such as translational
bioinformatics, bioethics etc.”With
an aim to provide a level playing
field for new entrants, the program
would open calls for research
proposals beginning August and
roll-out in October this year.
The mission was launched in the
presence of Dr K VijayRaghavan,
Secretary, Department of
Biotechnology; Junaid Ahmad,
Country Director, World Bank
India; dignitaries from the
BIOVOICENEWS.COM
45